CPHI CHINA PHARMA HOLDINGS, INC.
Pharmaceutical Preparations · NYSE · SEC CIK 1106644 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.0%
TTM net income YoY-22.4%
TTM EPS YoY71.6%
Revenue 3-yr CAGR-21.0%
Net income 3-yr CAGR—
Margins
Gross margin11.8%
Operating margin-111.8%
Net margin-114.3%
FCF margin—
EBITDA margin-66.2%
Returns
ROE-21.0%
ROA-15.3%
ROIC (approx.)-16.6%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets19.1%
Debt / equity0.00x
Current ratio0.26x
Interest coverage-136.51x
Cash quality & payout
Operating cash flow / net income0.04x
Accruals ratio-14.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.14M | $4.53M | $7.01M | $8.10M | $9.64M |
| Cost of revenue | $4.28M | $6.51M | $7.29M | $8.60M | $9.29M |
| Gross profit | -$131,950 | -$1.99M | -$281,085 | -$493,916 | $349,270 |
| R&D expense | $280,901 | $283,942 | $240,080 | $185,858 | $318,964 |
| SG&A expense | $2.45M | $1.78M | $1.47M | $1.89M | $1.65M |
| Operating income | -$3.24M | -$4.59M | -$2.75M | -$3.55M | -$2.86M |
| Interest expense | $27,272 | $27,353 | $30,572 | $434,619 | $542,001 |
| Pretax income | -$3.19M | -$4.74M | -$3.08M | -$3.97M | -$3.40M |
| Net income | -$3.19M | -$4.74M | -$3.08M | -$3.97M | -$3.40M |
| EBITDA | -$1.74M | -$1.97M | $1,833 | -$848,444 | $227,310 |
| EPS (basic) | -0.74 | -2.71 | -0.91 | -3.78 | -0.74 |
| EPS (diluted) | -0.74 | -2.71 | -0.91 | -3.78 | -0.74 |
| Weighted avg. shares (diluted) | — | — | — | — | 46.13M |
| Balance sheet | |||||
| Cash & equivalents | $345,112 | $626,879 | $1.42M | $2.03M | $4.86M |
| Receivables | $241,412 | $232,140 | $504,448 | $421,531 | — |
| Inventory | $1.62M | $2.27M | $3.73M | $2.95M | $2.95M |
| Current assets | $2.35M | $3.27M | $6.00M | $5.96M | $9.09M |
| PP&E, net | $4.39M | $4.88M | $7.10M | $9.97M | $13.28M |
| Intangibles | $24.08M | $6.70M | $3.26M | $1.81M | $147,841 |
| Total assets | $31.00M | $14.89M | $16.47M | $17.78M | $22.65M |
| Current liabilities | $7.40M | $5.02M | $6.82M | $12.74M | $10.51M |
| Short-term debt | $1.44M | $1.14M | $1.13M | — | — |
| Total liabilities | $8.26M | $7.14M | $9.01M | $13.49M | $16.63M |
| Shareholders' equity | $22.74M | $7.75M | $7.45M | $4.29M | $6.02M |
| Shares outstanding | 5.52M | 3.26M | 10.63M | 1.50M | 4.73M |
| Cash flow statement | |||||
| Operating cash flow | $148,261 | -$406,063 | -$699,686 | -$409,545 | -$249,838 |
| Capital expenditure | $59,324 | $38,411 | $11,517 | $401,964 | $438,055 |
| Free cash flow | $88,937 | -$444,474 | -$711,203 | -$811,509 | -$687,893 |
| Investing cash flow | -$137,251 | -$291,718 | -$11,517 | -$401,964 | -$438,055 |
| Financing cash flow | -$294,027 | -$33,782 | $73,145 | -$1.77M | $4.60M |
| Depreciation & amortization | $1.50M | $2.62M | $2.75M | $2.70M | $3.09M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.